GB201715194D0 - Compounds and their therapeutic use - Google Patents

Compounds and their therapeutic use

Info

Publication number
GB201715194D0
GB201715194D0 GBGB1715194.5A GB201715194A GB201715194D0 GB 201715194 D0 GB201715194 D0 GB 201715194D0 GB 201715194 A GB201715194 A GB 201715194A GB 201715194 D0 GB201715194 D0 GB 201715194D0
Authority
GB
United Kingdom
Prior art keywords
compounds
therapeutic use
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1715194.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Ip2ipo Innovations Ltd
Carrick Therapeutics Ltd
Original Assignee
Imperial Innovations Ltd
Cancer Research Technology Ltd
Carrick Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd, Cancer Research Technology Ltd, Carrick Therapeutics Ltd filed Critical Imperial Innovations Ltd
Priority to GBGB1715194.5A priority Critical patent/GB201715194D0/en
Publication of GB201715194D0 publication Critical patent/GB201715194D0/en
Priority to US16/648,011 priority patent/US11857552B2/en
Priority to NZ763316A priority patent/NZ763316B2/en
Priority to AU2018335841A priority patent/AU2018335841B2/en
Priority to EP18773442.1A priority patent/EP3684769B1/en
Priority to PCT/EP2018/075482 priority patent/WO2019057825A1/en
Priority to MA050161A priority patent/MA50161A/fr
Priority to CA3075461A priority patent/CA3075461C/en
Priority to JP2020517114A priority patent/JP7148604B2/ja
Priority to BR112020005279-5A priority patent/BR112020005279B1/pt
Priority to CN201880074480.2A priority patent/CN111566106B/zh
Priority to IL273396A priority patent/IL273396B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1715194.5A 2017-09-20 2017-09-20 Compounds and their therapeutic use Ceased GB201715194D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB1715194.5A GB201715194D0 (en) 2017-09-20 2017-09-20 Compounds and their therapeutic use
CN201880074480.2A CN111566106B (zh) 2017-09-20 2018-09-20 作为cdk抑制剂的化合物
EP18773442.1A EP3684769B1 (en) 2017-09-20 2018-09-20 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as cdk inhibitors
NZ763316A NZ763316B2 (en) 2018-09-20 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as cdk inhibitors
AU2018335841A AU2018335841B2 (en) 2017-09-20 2018-09-20 4-(((7-aminopyrazolo(1,5-a)pyrimidin-5-yl)amino)methyl)piperidin-3-ol compounds as CDK inhibitors
US16/648,011 US11857552B2 (en) 2017-09-20 2018-09-20 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors
PCT/EP2018/075482 WO2019057825A1 (en) 2017-09-20 2018-09-20 4 - [[(7-AMINOPYRAZOLO [1,5-A] PYRIMIDIN-5-YL) AMINO] METHYL] PIPERIDIN-3-OL COMPOUNDS AS CDK INHIBITORS
MA050161A MA50161A (fr) 2017-09-20 2018-09-20 Composés de 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]méthyl]pipéridin-3-ol utilisés en tant qu'inhibiteurs de cdk
CA3075461A CA3075461C (en) 2017-09-20 2018-09-20 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as cdk inhibitors
JP2020517114A JP7148604B2 (ja) 2017-09-20 2018-09-20 CDK阻害剤としての4-[[(7-アミノピラゾロ[1,5-a]ピリミジン-5-イル)アミノ]メチル]ピペリジン-3-オール化合物
BR112020005279-5A BR112020005279B1 (pt) 2017-09-20 2018-09-20 Compostos de 4-[[(7-aminopirazolo[1,5-a]pirimidin-5- il)amino]metil] piperidin-3-ol como inibidores cdk, seus usos, composição farmacêutica e seu método de preparação, métodos in vitro para inibir a função de cdk em uma célula, e para inibir a proliferação celular, inibir a progressão do ciclo celular, promover apoptose ou uma combinação de um ou mais desses, e kit
IL273396A IL273396B2 (en) 2017-09-20 2020-03-18 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as cdk inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1715194.5A GB201715194D0 (en) 2017-09-20 2017-09-20 Compounds and their therapeutic use

Publications (1)

Publication Number Publication Date
GB201715194D0 true GB201715194D0 (en) 2017-11-01

Family

ID=60159506

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1715194.5A Ceased GB201715194D0 (en) 2017-09-20 2017-09-20 Compounds and their therapeutic use

Country Status (11)

Country Link
US (1) US11857552B2 (cg-RX-API-DMAC7.html)
EP (1) EP3684769B1 (cg-RX-API-DMAC7.html)
JP (1) JP7148604B2 (cg-RX-API-DMAC7.html)
CN (1) CN111566106B (cg-RX-API-DMAC7.html)
AU (1) AU2018335841B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020005279B1 (cg-RX-API-DMAC7.html)
CA (1) CA3075461C (cg-RX-API-DMAC7.html)
GB (1) GB201715194D0 (cg-RX-API-DMAC7.html)
IL (1) IL273396B2 (cg-RX-API-DMAC7.html)
MA (1) MA50161A (cg-RX-API-DMAC7.html)
WO (1) WO2019057825A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201715194D0 (en) 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
US20220144841A1 (en) * 2019-03-13 2022-05-12 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
US20230348475A1 (en) * 2020-09-17 2023-11-02 The Translational Genomics Research Institute Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7
GB202108572D0 (en) 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN120752238A (zh) * 2023-02-20 2025-10-03 江苏正大丰海制药有限公司 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
CN117899202B (zh) * 2024-01-19 2024-11-26 杭州师范大学 Cdk12蛋白及其编码基因在制备抗病毒药物中的应用
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
CN122124058B (zh) * 2026-04-30 2026-08-04 襄阳市中心医院 Cvt-313在制备抗猴痘病毒药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396693A1 (en) 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
JP4881558B2 (ja) 2002-09-04 2012-02-22 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2006516573A (ja) 2003-01-31 2006-07-06 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての3−アミノ−4−フェニルブタン酸誘導体
JP4564485B2 (ja) 2003-02-28 2010-10-20 帝人ファーマ株式会社 ピラゾロ[1,5−a]ピリミジン誘導体
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
JP2010529140A (ja) 2007-06-05 2010-08-26 エモリー・ユニバーシテイ サイクリン依存性キナーゼの選択的阻害剤
PL2509602T3 (pl) 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201715194D0 (en) 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use

Also Published As

Publication number Publication date
EP3684769A1 (en) 2020-07-29
CA3075461C (en) 2023-12-05
AU2018335841B2 (en) 2023-03-16
US20200345736A1 (en) 2020-11-05
IL273396A (en) 2020-05-31
CN111566106B (zh) 2023-03-10
AU2018335841A1 (en) 2020-04-23
BR112020005279A2 (pt) 2020-09-24
EP3684769B1 (en) 2022-01-12
BR112020005279B1 (pt) 2024-01-09
CN111566106A (zh) 2020-08-21
WO2019057825A1 (en) 2019-03-28
IL273396B2 (en) 2023-02-01
IL273396B (en) 2022-10-01
NZ763316A (en) 2023-09-29
US11857552B2 (en) 2024-01-02
JP7148604B2 (ja) 2022-10-05
MA50161A (fr) 2021-05-19
JP2020534346A (ja) 2020-11-26
CA3075461A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
GB201709456D0 (en) Therapeutic agents
GB201403093D0 (en) Therapeutic compounds and their use
ZA201802256B (en) Compounds and therapeutic uses thereof
GB201617064D0 (en) Compounds and their therapeutic use
IL277749A (en) Palladianolide compounds and their use
GB201813312D0 (en) Compounds and their therapeutic use
IL270011B (en) Medicinal compounds and methods
GB201918541D0 (en) Therapeutic compounds and their use
IL265269B (en) New compounds and their medicinal uses
GB201608797D0 (en) Therapeutic use
IL257932A (en) Adapted cytotoxins and their therapeutic uses
IL257559B (en) Hydroxytriazine compound and its medicinal use
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
GB201700526D0 (en) Therapeutic use
GB201816553D0 (en) Novel compounds and therapeutic uses thereof
GB201816554D0 (en) Novel compounds and therapeutic uses thereof
IL270460B1 (en) New compounds and their medicinal uses
GB201700553D0 (en) Therapeutic agents
GB201418809D0 (en) Therapeutic agents and uses thereof
GB201804098D0 (en) Novel compounds and therapeutic uses thereof
PL3341481T3 (pl) Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne
GB201705684D0 (en) Novel compounds and therapeutic uses thereof
GB201707076D0 (en) Novel compounds and therapeutic uses thereof
GB2558788B (en) New therapeutic uses
GB201705685D0 (en) Novel compounds and therapeutic uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)